Support our sponsors:

NZX 50 Index	3315.14	2.90
S&P/ASX 200	4274.20	21.80
Dow Jones Industrials	12845.10	17.10

Twitter

Facebook

RSS

Daily ShareChat: Fisher & Paykel Healthcare

By Jenny Ruth

Monday 25th May 2009

Text too small?

Fisher & Paykel Healthcare is likely to report a 71% rise in annual net earnings to $60 million on Tuesday, close to the company's guidance provided when it reported its first-half results, says Guy Hallwright at Forsyth Barr.

That guidance was based on the New Zealand dollar averaging 55 US cents through the second half and it ended up averaging slightly above that level.

He expects revenue from the company's acute and respiratory products will be in line with guidance of slightly below 15% in US dollar terms.

Revenue from its obstructive sleep apnea (OSA) products, also expected to be about 15%, could disappoint slightly because "lower-level OSA treatment may have a discretionary element in recessionary times," Hallwright says.

The company "continues to make steady progress into non-ICU respiratory therapy, laparoscopic insufflation and new masks and auto-sensing flow generators in OSA."

Hallwright says Fisher & Paykel Healthcare's growth outlook is driven by continued product innovation and strong growth in the global OSA market as well as increasing consumables (such as masks) sales. Expansion outside intensive care in respiratory humidification could potentially double or triple the company's addressable market, he says.

While the company's earnings have been severely impacted by the strong New Zealand dollar in recent years, "we believe we are finally seeing a sustained fall."

BROKER CALL: Forsyth Barr rate Fisher & Paykel Healthcare (NZX: FPH ) as BUY.

Daily ShareChat articles report how the main experts in the market might view a certain share and we provide this commentary as a useful resource for investors. Content on this site does not in any way constitute a recommendation to buy, hold or sell any particular share. Investors should always seek professional advice before making any investment decisions.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.